GoodRx Holdings, Inc. Class A Common Stock (GDRX) is a publicly traded Healthcare sector company. As of May 21, 2026, GDRX trades at $2.52 with a market cap of $846.69M and a P/E ratio of 41.75. GDRX moved -0.20% today. Year to date, GDRX is -10.95%; over the trailing twelve months it is -36.52%. Its 52-week range spans $1.77 to $7.21. Analyst consensus is neutral with an average price target of $3.09. Rallies surfaces GDRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GoodRx Q4 Sales Beat Estimates by 0.8% at $194.8M, 2026 EBITDA Guidance Cut to $230M: GoodRx’s Q4 CY2025 revenue declined 1.9% year-on-year to $194.8 million, topping estimates by 0.8% while non-GAAP EPS stayed flat at $0.09. The company cut fiscal 2026 EBITDA guidance to $230 million—18.5% below analysts’ $282.1 million forecast—sending the stock down 11.8%.
| Metric | Value |
|---|---|
| Price | $2.52 |
| Market Cap | $846.69M |
| P/E Ratio | 41.75 |
| EPS | $0.06 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.21 |
| 52-Week Low | $1.77 |
| Volume | 62.86K |
| Avg Volume | 0 |
| Revenue (TTM) | $787.89M |
| Net Income | $20.56M |
| Gross Margin | 0.00% |
13 analysts cover GDRX: 0 strong buy, 4 buy, 7 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $3.09.